Key Takeaways
- • AQR Capital Management employs a market-neutral betting-against-beta (BAB) strategy that takes long positions in leveraged low-beta assets while shorting high-beta assets, exploiting the empirical finding that constrained investors systematically overbid risky securities, depressing their risk-adjusted returns.
- • The BAB factor generates risk-adjusted returns that rival established asset-pricing factors including value, momentum, and size in terms of economic magnitude, statistical significance, and consistency across time periods, geographies, and asset classes.
- • The strategy is grounded in leverage constraints affecting institutional investors (pension funds, mutual funds, individuals) that cannot freely leverage portfolios, forcing them to overweight beta rather than optimize Sharpe ratios as standard CAPM assumes, creating a persistent market inefficiency.
- • BAB performance is empirically validated across 20 international equity markets, Treasury bonds, corporate bonds, and futures markets, with evidence that the security market line flattens relative to CAPM predictions in 18 of 19 international equity markets tested.
- • BAB factor returns compress during periods of funding constraint tightening, indicating the strategy's performance depends on liquidity conditions and arbitrage capacity rather than representing a pure risk premium.
Summary
AQR Capital Management, founded by Cliff Asness, has developed the betting-against-beta (BAB) strategy as a systematic approach to exploit a fundamental deviation from classical capital asset pricing model (CAPM) assumptions. The core insight underlying this strategy addresses a structural market inefficiency: many institutional investors—including pension funds, mutual funds, and individual investors—face regulatory or practical constraints on leverage and cannot borrow freely to optimize their portfolios. As a result, these constrained investors systematically overweight high-beta (riskier) securities to achieve desired portfolio returns, artificially depressing the risk-adjusted returns of those high-beta assets.
The BAB strategy capitalizes on this behavior by constructing market-neutral portfolios that are long leveraged low-beta assets and short high-beta assets. This zero-cost, zero-beta approach is designed to isolate and profit from the mispricing of beta itself, independent of market direction or overall systematic risk exposure. Research by Andrea Frazzini and Lasse Pedersen, conducted at AQR and affiliated institutions, demonstrates that the BAB factor produces significant positive risk-adjusted returns by exploiting the empirical flatness of the security market line relative to CAPM predictions.
The empirical validation is extensive: the BAB factor's return premium rivals that of all major established factors—value, momentum, and size—in terms of both economic magnitude and statistical significance. This consistency holds across diverse time periods, geographic markets (18 of 19 international equity markets tested show relative flatness), and asset classes including equities, Treasury bonds, corporate bonds, and futures contracts across 20 countries. AQR provides monthly updated data on BAB factors for U.S. equities and 23 international equity markets, underscoring the systematic and reproducible nature of the strategy.
Critically, BAB performance is not a pure risk premium but reflects the interaction between investor constraints and liquidity conditions. When funding constraints tighten—as occurs during market stress or credit crunches—BAB returns compress, indicating that the strategy's profitability depends on the ability to execute leverage-constrained arbitrage. This conditional performance characteristic distinguishes BAB from traditional factor exposures and highlights its sensitivity to limit-of-arbitrage conditions that affect short-selling capacity and funding availability.
The BAB strategy capitalizes on this behavior by constructing market-neutral portfolios that are long leveraged low-beta assets and short high-beta assets. This zero-cost, zero-beta approach is designed to isolate and profit from the mispricing of beta itself, independent of market direction or overall systematic risk exposure. Research by Andrea Frazzini and Lasse Pedersen, conducted at AQR and affiliated institutions, demonstrates that the BAB factor produces significant positive risk-adjusted returns by exploiting the empirical flatness of the security market line relative to CAPM predictions.
The empirical validation is extensive: the BAB factor's return premium rivals that of all major established factors—value, momentum, and size—in terms of both economic magnitude and statistical significance. This consistency holds across diverse time periods, geographic markets (18 of 19 international equity markets tested show relative flatness), and asset classes including equities, Treasury bonds, corporate bonds, and futures contracts across 20 countries. AQR provides monthly updated data on BAB factors for U.S. equities and 23 international equity markets, underscoring the systematic and reproducible nature of the strategy.
Critically, BAB performance is not a pure risk premium but reflects the interaction between investor constraints and liquidity conditions. When funding constraints tighten—as occurs during market stress or credit crunches—BAB returns compress, indicating that the strategy's profitability depends on the ability to execute leverage-constrained arbitrage. This conditional performance characteristic distinguishes BAB from traditional factor exposures and highlights its sensitivity to limit-of-arbitrage conditions that affect short-selling capacity and funding availability.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.